Key result
Higher hs-cTnT improves HFpEF diagnostic accuracy and is linked to ~30% higher all-cause mortality.
Why the study?
To assess if cardiac troponins can improve diagnostics of acute heart failure and provide prognostic information in patients with acute dyspnea.
Does hs-cTnT measurement improve diagnosis of HFpEF and predict mortality in patients hospitalized with acute dyspnea?
Cohort (n=314)
Does hs-cTnT measurement improve diagnosis of HFpEF and predict mortality in patients hospitalized with acute dyspnea?
Hazard Ratio: 1.3 (95% CI 1.07–1.58)
p-value: p=0.009
hs-cTnT measurement improves the diagnostic accuracy for HFpEF and provides independent prognostic information for all-cause mortality in patients presenting with acute dyspnea.
hs-cTnT may aid HFpEF diagnosis and mortality risk stratification in acute dyspnea; leaves open whether it improves outcomes or guides therapy.
BACKGROUND: To assess if cardiac troponins can improve diagnostics of acute heart failure (AHF) and provide prognostic information in patients with acute dyspnea. METHODS: We measured cardiac troponin T with a high-sensitivity assay (hs-cTnT) in 314 patients hospitalized with acute dyspnea. The index diagnosis was adjudicated and AHF patients were stratified into AHF with reduced or preserved ejection fraction (HFrEF/HFpEF). The prognostic and diagnostic merit of hs-cTnT was compared to the merit of N-terminal pro-B-type natriuretic peptide (NT-proBNP). RESULTS: In the total population, median age was 73 (quartile [Q] 1-3 63-81) years and 48% were women. One-hundred-forty-three patients were categorized as AHF (46%) and these patients had higher hs-cTnT concentrations than patients with non-AHF-related dyspnea: median 38 (Q1-3 22-75) vs. 13 (4-25) ng/L; p < 0.001. hs-cTnT concentrations were similar between patients with HFrEF and HFpEF (p = 0.80), in contrast to NT-proBNP, which was higher in HFrEF (p < 0.001). C-statistics for discriminating HFpEF from non-AHF-related dyspnea was 0.80 (95% CI 0.73-0.86) for hs-cTnT, 0.79 (0.73-0.86) for NT-proBNP, and 0.83 (0.76-0.89) for hs-cTnT and NT-proBNP in combination. Elevated hs-cTnT remained associated with HFpEF in logistic regression analysis after adjusting for demographics, comorbidities and renal function. During median 27 months of follow-up, 114 (36%) patients died in the total population. Higher hs-cTnT concentrations were associated with increased risk of all-cause mortality after adjustment for clinical variables and NT-proBNP: hazard ratio 1.30 (95% CI 1.07-1.58), p = 0.009. CONCLUSION: hs-cTnT measurements improve diagnostic accuracy for HFpEF and provide independent prognostic information in unselected patients with acute dyspnea.
No takes yet. Share an insight, caveat, or question.
Berge et al. (2020) conducted a cohort in acute dyspnea (n=314). High-sensitivity cardiac troponin T (hs-cTnT) vs. NT-proBNP was evaluated on all-cause mortality (HR 1.30, 95% CI 1.07-1.58, p=0.009). Higher hs-cTnT concentrations improved diagnostic accuracy for HFpEF (C-statistic 0.80) and were associated with an increased risk of all-cause mortality (HR 1.30; 95% CI 1.07-1.58; p=0.009).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: